ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 689,83
0,36%
Dow Jones
39 112,16
-0,76%
DAX
18 327,39
0,91%
Brent Oil
84,545
0,43%
Bitcoin
61 514,25
-0,48%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Scilex Holding Company (SCLX)

  7. Scilex Holding Company (SCLX) Actualités

SCLX

Scilex (SCLX)

Scilex Holding Company
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:SCLX
DateHeureSourceTitreSymboleSociété
20/06/202415h00GlobeNewswire Inc.Scilex Holding Company Partners with New National Distributor, Endeavor Distribution LLC.NASDAQ:SCLXScilex Holding Company
14/06/202419h41GlobeNewswire Inc.Scilex Holding Company Announces Publication in PAIN Journal Regarding Phase 3 Results of the Pivotal Registration Trial of SP-102 (SEMDEXA™) in Lumbosacral Radicular Pain (Sciatica)NASDAQ:SCLXScilex Holding Company
13/06/202415h00GlobeNewswire Inc.Scilex Holding Company to Present Poster on ELYXYB® (celecoxib oral solution) at the 66th Annual Scientific Meeting of the American Headache Society (AHS) to be Held in San Diego, CA on June 13-16, 2024NASDAQ:SCLXScilex Holding Company
12/06/202421h37AllPennyStocks.comPharma Shares Pop After Securing $100M Of FinancingNASDAQ:SCLXScilex Holding Company
12/06/202401h20GlobeNewswire Inc.Scilex Holding Company Announces 5-Year Term of $100 Million Financing with Royalty-Based Payments and Potential Strategic Transactions with Perigrove and its Portfolio CompaniesNASDAQ:SCLXScilex Holding Company
11/06/202415h00GlobeNewswire Inc.Scilex Holding Company Announces That Many National Pharmacy Chains and Independent Pharmacies Have Begun Stocking GLOPERBA®NASDAQ:SCLXScilex Holding Company
10/06/202417h49GlobeNewswire Inc.Scilex Holding Company Announces Stocking of GLOPERBA® is Underway in all of the Wholesalers with which Scilex has Stocking Arrangements Throughout the U.S.NASDAQ:SCLXScilex Holding Company
06/06/202420h56GlobeNewswire Inc.Scilex Holding Company announces the U.S. FDA has approved the sNDA for commercial manufacturing of Gloperba® which will be launched in the US in the week of June 10th 2024NASDAQ:SCLXScilex Holding Company
30/05/202419h19GlobeNewswire Inc.Scilex Holding Company Sends Letters to the U.S. Securities and Exchange Commission and Financial Industry Regulatory Authority Regarding Illegal Market Manipulation of the Common Stock of Scilex Holding CompanyNASDAQ:SCLXScilex Holding Company
24/05/202419h40GlobeNewswire Inc.Scilex Holding Company Announces it has been Added to the MSCI Global Microcap IndexNASDAQ:SCLXScilex Holding Company
24/05/202415h00GlobeNewswire Inc.Scilex Holding Company Sends Letter to U.S. House of Representatives on Illegal Market Manipulation of the Common Stock of Scilex Holding CompanyNASDAQ:SCLXScilex Holding Company
14/05/202415h00GlobeNewswire Inc.Scilex Holding Company Announces Final Court Approval of a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex’s intent to Expand the Label for its FDA-Approved Liquid Colchicine ProNASDAQ:SCLXScilex Holding Company
13/05/202415h00GlobeNewswire Inc.Scilex Holding Company Provides Information to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common StockNASDAQ:SCLXScilex Holding Company
25/04/202422h01GlobeNewswire Inc.Scilex Holding Company Announces Closing of $15 Million Registered Direct OfferingNASDAQ:SCLXScilex Holding Company
24/04/202414h00GlobeNewswire Inc.Scilex Holding Company Announces $15 Million Registered Direct OfferingNASDAQ:SCLXScilex Holding Company
16/04/202415h00GlobeNewswire Inc.Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross and Net Sales for ZTlido® for the First Quarter 2024; Implements Planned 2024 Commercial Ramp for Additional Opioid Sparing Product and Reduction of R&D and Other AdNASDAQ:SCLXScilex Holding Company
09/04/202415h00GlobeNewswire Inc.Scilex Holding Company Announces Launching of Co-Pay Programs for Both ZTlido® and ELYXYB® for Commercially Insured Patients and the addition of ELYXYB® to a Multi-State Medicaid Pharmaceutical Purchasing Group to Its Purchasing PoolNASDAQ:SCLXScilex Holding Company
27/03/202414h00GlobeNewswire Inc.Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a DividendNASDAQ:SCLXScilex Holding Company
21/03/202414h30GlobeNewswire Inc.Scilex Holding Company Announces New Out-of-Pocket Costs for Commercially Insured PatientsNASDAQ:SCLXScilex Holding Company
20/03/202416h00GlobeNewswire Inc.Scilex Holding Company Announces Seeking Approval from the FDA for Modification of the Gloperba® Label to Provide Specific Dosing Guidance for Patients with Renal Impairment and Other Circumstances Where Dose Adjustment is NeededNASDAQ:SCLXScilex Holding Company
20/03/202414h00GlobeNewswire Inc.Scilex Holding Company Announces a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex’s Filing of a sNDA with the FDA Seeking to Expand the Label for its FDA-Approved Liquid ColchicNASDAQ:SCLXScilex Holding Company
19/03/202414h00GlobeNewswire Inc.Scilex Holding Company Announces Repayment in Full of the Remaining Balance of Convertible Debentures and Early Payment of the Senior Secured Promissory Note, Paving the Way for Future Growth and InnovationNASDAQ:SCLXScilex Holding Company
18/03/202414h00GlobeNewswire Inc.Scilex Holding Company Provides Responses to Product Composition Questions Related to its ELYXYB® Patent in Canada for a New Drug Submission Under Review by Health Canada for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura inNASDAQ:SCLXScilex Holding Company
15/03/202419h45GlobeNewswire Inc.Scilex Holding Announces Issuance of Halal Certification for its ZTlido® product by Circle H International, Inc.NASDAQ:SCLXScilex Holding Company
15/03/202414h00GlobeNewswire Inc.Scilex Holding Company’s Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Entered into a Definitive Mutual Release and Settlement Agreement with Virpax Pharmaceuticals, Inc. Relating to the Previously Announced Term Sheet with Virpax in Respect of SNASDAQ:SCLXScilex Holding Company
11/03/202405h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SCLXScilex Holding Company
05/03/202422h22Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:SCLXScilex Holding Company
05/03/202422h20Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:SCLXScilex Holding Company
05/03/202422h12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SCLXScilex Holding Company
05/03/202422h01GlobeNewswire Inc.Scilex Holding Company Announces Closing of $10 Million Bought Deal OfferingNASDAQ:SCLXScilex Holding Company
 Showing the most relevant articles for your search:NASDAQ:SCLX

Dernières Valeurs Consultées

NASDAQ
USEYE
U.S. Energy Systems
BIT
UC6M1G
Unicredit Bank
EU
5569T
5569T
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés